Natixis Advisors, L.P. Aerie Pharmaceuticals Inc Transaction History

Natixis Advisors, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $1,165 - $2,787	183 Added 0.49%	37,375 $565,000
Q2 2022 Aug 12, 2022	SELL	$4.95 - $9.16 $1,089 - $2,015	-220 Reduced 0.59%	37,192 $279,000
Q1 2022 May 12, 2022	BUY	$5.64 - $9.8 $211,003 - $366,637	37,412 New	37,412 $340,000
Q4 2021 Feb 08, 2022	SELL	$7.02 - $13.33 $167,097 - $317,293	-23,803 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $2,931 - $4,307	-259 Reduced 1.08%	23,803 $271,000

Q2 2021 Aug 12, 2021	SELL	$15.16 - $18.97 $5,836 - $7,303	-385 Reduced 1.57%	24,062 $385,000
Q1 2021 May 05, 2021	SELL	$13.12 - $20.9 $16,951 - $27,002	-1,292 Reduced 5.02%	24,447 $436,000
Q4 2020 Feb 12, 2021	BUY	$9.12 - $14.49 $234,739 - $372,958	25,739 New	25,739 $348,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.